MedPath

Redx Pharma Plc

Redx Pharma Plc logo
🇬🇧United Kingdom
Ownership
Public
Established
2010-01-01
Employees
51
Market Cap
-
Website
http://www.redxpharma.com

Clinical Trials

9

Active:5
Completed:4

Trial Phases

2 Phases

Phase 1:6
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (66.7%)
Phase 2
3 (33.3%)

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Phase 2
Active, not recruiting
Conditions
IPF
Fibrosis
Interventions
Drug: Placebo
First Posted Date
2022-10-06
Last Posted Date
2024-08-23
Lead Sponsor
Redx Pharma Plc
Target Recruit Count
48
Registration Number
NCT05570058
Locations
🇦🇹

Medical University of Vienna, Wien, Austria

🇧🇪

E PNE UZ Leuven, Leuven, Belgium

🇧🇪

CHU De Liège, Liège, Belgium

and more 28 locations

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Phase 1
Completed
Conditions
Inflammation
Idiopathic Pulmonary Fibrosis
Liver Diseases
Kidney Diseases
Non-alcoholic Steatohepatitis
Fibrosis
Interventions
Drug: RXC007 Matching Placebo
First Posted Date
2021-06-18
Last Posted Date
2023-11-18
Lead Sponsor
Redx Pharma Plc
Target Recruit Count
90
Registration Number
NCT04931147
Locations
🇬🇧

Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Mid Glamorgan, United Kingdom

A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

Phase 2
Completed
Conditions
Advanced Solid Tumours
Interventions
First Posted Date
2021-06-01
Last Posted Date
2025-03-17
Lead Sponsor
Redx Pharma Ltd
Target Recruit Count
45
Registration Number
NCT04907851
Locations
🇦🇺

Wollongong Hospital, Wollongong, New South Wales, Australia

🇦🇺

The Alfred Hospital - Alfred Health, Melbourne, Victoria, Australia

🇬🇧

Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom

and more 10 locations

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2021-05-28
Last Posted Date
2025-04-16
Lead Sponsor
Redx Pharma Ltd
Target Recruit Count
25
Registration Number
NCT04907539
Locations
🇺🇸

Providence Medical Foundation, Santa Rosa, California, United States

🇺🇸

Community Health Network Cancer Center North - Community Hospital Network, Indianapolis, Indiana, United States

🇺🇸

OptumCare Cancer Care, Las Vegas, Nevada, United States

and more 19 locations

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Phase 1
Completed
Conditions
Cancer
Solid Tumor
Interventions
First Posted Date
2018-02-27
Last Posted Date
2025-01-29
Lead Sponsor
Redx Pharma Ltd
Target Recruit Count
46
Registration Number
NCT03447470
Locations
🇬🇧

Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, United Kingdom

🇬🇧

Guys Hospital, London, United Kingdom

🇬🇧

The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.